Compare JBTM & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JBTM | GKOS |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | 11500 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.0B |
| IPO Year | N/A | 2015 |
| Metric | JBTM | GKOS |
|---|---|---|
| Price | $131.39 | $120.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $180.00 | $133.07 |
| AVG Volume (30 Days) | 452.1K | ★ 637.6K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $8.10 | $23.30 |
| Revenue Next Year | $4.68 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $90.21 | $73.16 |
| 52 Week High | $170.19 | $130.23 |
| Indicator | JBTM | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 63.24 |
| Support Level | $131.69 | $81.54 |
| Resistance Level | $146.30 | $123.16 |
| Average True Range (ATR) | 4.40 | 4.49 |
| MACD | 1.60 | 1.62 |
| Stochastic Oscillator | 69.05 | 91.29 |
JBT Marel Corp operates through two reportable segments: Protein Solutions and Prepared Food and Beverage Solutions. The Protein Solutions segment includes businesses that provide solutions for the initial stage processing and harvesting of animal proteins, mainly focusing on poultry, pork, fish, and beef. The Prepared Food and Beverage Solutions segment includes businesses that offer solutions predominantly for downstream value-added preparation, preservation, and packaging of foods and beverages into ready-to-eat or drink products. This segment will also include capabilities for pet food, dairy, bakery, pharmaceutical, nutraceutical, and warehouse automation end markets. The majority of its revenue is generated from the Prepared Food and Beverage Solutions segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.